2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Art. -Nr. Produktname CAS. Nr. Reinheit Chemische Struktur
  • HY-P10466
    KZR-8445 2377734-91-1 98%
    KZR-8445, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 inhibits SARS-CoV-2 replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection.
    KZR-8445
  • HY-P10469
    NBD-2 98%
    NBD-2 is an inhibitor of the NEMO-IKKα/β interaction in the NF-κB signaling pathway. NBD-2 specifically inhibits the typical NF-κB signaling pathway in vitro and in vivo, reducing the inflammatory response in lipopolysaccharide (LPS) induced acute lung injury (ALI). NBD-2 exhibits significant anti-inflammatory activity. NBD-2 can be used to study diseases related to NF-κB signaling pathway, including autoimmune diseases, cancer, etc.
    NBD-2
  • HY-P10473
    CPN-351 3057171-63-5 98%
    CPN-351 (compound 9a), a pentapeptide, is a selective antagonist of human NMUR1 with a pA2 of 7.35. The antagonistic effect of CPN-351 on human NMUR1 is 10 times higher than that on NMUR2. CPN-351 can be used in the study of inflammation.
    CPN-351
  • HY-P10497
    EBV BZLF1 (190-197) 200124-17-0 98%
    EBV BZLF1 (190-197) is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV). EBV BZLF1 (190-197) is a suitable epitope for CD8+ T cells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) can be used to study autoimmune diseases.
    EBV BZLF1 (190-197)
  • HY-P10572
    HG1 Toxin 98%
    HG1 Toxin is a peptide found in the venom of the scorpion Heterometrus fulvipes, which has the activity of inhibiting potassium channel Kv1.3. HG1 Toxin also has the activity of inhibiting trypsin (Ki=107 nM) and can be used in the study of autoimmune diseases.
    HG1 Toxin
  • HY-P10619
    [Tyr6,D-Phe7,D-His9]-Substance P (6-11) 145194-26-9 98%
    [Tyr6,D-Phe7,D-His9]-Substance P (6-11) is a tachykinin NK1 receptor antagonist that antagonizes Histamine (HY-B1204) induced hyperalgesia.
    [Tyr6,D-Phe7,D-His9]-Substance P (6-11)
  • HY-P10631
    gp96-II 98%
    Gp96-II is a gp96-blocking peptide that antagonizes gp96-mediated LPS(HY-D1056)-induced cytokine production. Gp96-II can be utilized in research on inflammatory disease.
    gp96-II
  • HY-P10635
    TKD (450-463) 403668-80-4 98%
    TKD (450-463) is a 14-mer peptide (TKDNNLLGRFELSG). TKD (450-463) is able to stimulate the cytolytic and proliferative activity of NK cells at concentrations equivalent to full-length Hsp70 protein.
    TKD (450-463)
  • HY-P10662
    HLA-B*0801-binding EBV peptide 139143-28-5 98%
    HLA-B*0801-binding EBV peptide is an Epstein-Barr virus (EBV) epitope FLRGRAYGL. HLA-B*0801-binding EBV peptide can bind to the HLA-B*0801 molecule. HLA-B*0801-binding EBV peptide can be presented to CD8+ T cells through HLA-B*0801 to activate a specific immune response.
    HLA-B*0801-binding EBV peptide
  • HY-P10663
    EBV EBNA3A (379-387) 160790-25-0 98%
    EBV EBNA3A (379-387) is an antigenic epitope that may elicit the latent-specific CD8+ T cell response in HLA-B*07:02+ individuals.
    EBV EBNA3A (379-387)
  • HY-P10692
    HB-107 135154-02-8 98%
    HB-107 is a peptide with wound healing properties. HB-107 promotes the proliferation of keratinocytes and increased leukocyte infiltration at the wound site, and it also stimulates cultured endothelial cells to secrete interleukin 8 (IL-8). HB-107 holds potential for research in the fields of wound healing and inflammation.
    HB-107
  • HY-P10693
    CZEN-002 942626-41-7 98%
    CZEN-002 is a derivative of alpha-melanocyte-stimulating hormone that has anti-inflammatory and antibacterial properties, inhibiting the production of TNF-α.
    CZEN-002
  • HY-P10694
    IDR-HH2 1214699-22-5 98%
    IDR-HH2 is an immunomodulatory peptide with the ability to modulate the host cytokine/chemokine environment. IDR-HH2 can promote the adhesion of monocytes and THP-1 cells to fibronectin. Additionally, IDR-HH2 possesses antibacterial activity, inhibiting the activity of both P. aeruginosa and S. aureus with MIC values of 75 µg/mL and 38 µg/mL, respectively.
    IDR-HH2
  • HY-P10701
    Q11 peptide 581799-39-5 98%
    Q11 peptide is a β-sheet-forming peptide that plays an important role in self-assembly and targeted applications. As a scaffold peptide, Q11 peptide can display immunogenic epitopes and is widely used in peptide-based immune vaccine research. Additionally, Q11 peptide can be conjugated with MUC1 glycopeptides for the study of self-assembling, adjuvant-free MUC1 glycopeptide vaccines. Q11 peptide holds great potential for research in the field of cancer immunology.
    Q11 peptide
  • HY-P10707
    Tpp-CAQK 98%
    Tpp-CAQK can bind to mitochondria, enabling the construction of an engineered mitochondrial compound, Mito-Tpp-CAQK, with excellent bioactivity. Mito-Tpp-CAQK can be internalized by macrophages, thereby enhancing the phagocytosis of myelin debris, alleviating mitochondrial dysfunction, and reducing proinflammatory profiles, ultimately facilitating tissue repair and functional recovery in mice after spinal cord injury.
    Tpp-CAQK
  • HY-P10710
    BMP-4 (15-24) 1629625-47-3 98%
    BMP-4 (15-24) is a cell-penetrating heparin-binding peptide with the sequence RKKNPNCRRH. BMP-4 (15-24) exhibits anti-inflammatory and anti-chondrogenic activities. BMP-4 (15-24) can be used in the research of arthritis.
    BMP-4 (15-24)
  • HY-P10715
    Fmoc-KCRGDK 98%
    Fmoc-KCRGDK is a self-assembling peptide that can be used to prepare hydrogels and assist in drug delivery for immune checkpoint inhibitors. Fmoc-KCRGDK can be applied in cancer immunotherapy research.
    Fmoc-KCRGDK
  • HY-P10768
    Ro 25-1553 159427-08-4 98%
    Ro 25-1553 is a selective VIP2 receptor (VPAC2 receptor) agonist. Ro 25-1553 exhibits bronchodilatory effects on tracheal smooth muscle contractions induced by nerve stimulation or Carbachol (HY-B1208). Ro 25-1553 produces a superimposed effect when combined with Formoterol and Salmeterol (HY-14302). Ro 25-1553 can be used for the study of bronchoconstriction.
    Ro 25-1553
  • HY-P10779
    flg22Pst 2268675-54-1 98%
    flg22Pst is a peptide that can be derived Pseudomonas syringae pv. tabaci and serves as an effective elicitor for the plant immune system. flg22Pst can induce callose deposition in plants, trigger plant immune responses, and thereby assist plants in defending against pathogen invasion.
    flg22Pst
  • HY-P10796
    YARA peptide 98%
    YARA peptide, a cell-penetrating peptide, is a MK2 inhibitor. YARA-loaded nanoparticles decreases the levels of inflammatory cytokines (IL-1β, IL-6, and TNF-α) in an ex vivo skin culture model. YARA peptide is promising for research of atopic dermatitis (AD).
    YARA peptide
Art. -Nr. Produktname / Synonyms Application Reactivity